(PRWEB UK) 1 May 2013
The new report 'Prostate Cancer Market Info' states that prostate cancer (PC) is the most common cancer in men and the second leading cancer-related killer behind lung cancer. It is a malignant adenocarcinoma that typically grows as small tumors in different areas of the gland. If detected and treated prior to spreading, 10-yr survival is over 90%. Treating PC is challenging because many tumors are indolent, not requiring treatment, while other tumors are aggressive and life threatening. Currently, there is no diagnostic to predict tumor aggressiveness.
Regardless of initial management, some men will present with or develop advanced disease that requires treatment. Androgen depletion therapy is the standard prostate cancer treatment that has advanced. When this fails, Taxotere is the chemotherapy that has shown increased overall survival. In the past two years, five new drugs have been approved for use in advanced prostate cancer expanding the market and dramatically changing patient management options.
View the report: 'Prostate Cancer Market Info'